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PDepression
etyrapone Improves Endothelial
ysfunction in Patients With Treated Depression
ndrew J. M. Broadley, MRCP,* Ania Korszun, MRCPSYCH,† Eltigani Abdelaal, MRCP,*
alentina Moskvina, PHD,‡ John Deanfield, FRCP,§ Christopher J. H. Jones, FRCP,†
ichael P. Frenneaux, FRCP, FACC*
irmingham and London, England; and Cardiff, Wales
OBJECTIVES This study sought to examine the effect of metyrapone on endothelial dysfunction in patients
with treated recurrent major depression.
BACKGROUND Depression is an independent risk factor for the development of coronary heart disease, and
patients with depression have endothelial dysfunction, an atherogenic abnormality. This
abnormality may be attributable to abnormal hypothalamic-pituitary-adrenal (HPA) axis
function, a feature of depression, resulting in increased exposure to cortisol. Cortisol
administration produces endothelial dysfunction in healthy subjects.
METHODS We measured endothelial function using flow-mediated dilation (FMD) of the brachial artery
in 30 patients with depression and in 36 matched control subjects. Patients were randomized
(double blind) to metyrapone (an inhibitor of cortisol synthesis) or placebo, and FMD was
remeasured 6 h later.
RESULTS At baseline, FMD was impaired in patients versus control subjects (mean [standard error]),
1.27% [0.91%] vs. 4.37% [0.59%] (p  0.001). The FMD was similar in the placebo and
the metyrapone patient groups at baseline (0.17% [1.04%] vs. 2.72% [1.30%], p  0.11).
Metyrapone significantly reduced plasma cortisol levels. There was a significant improvement
in FMD in the metyrapone group from 2.72% [1.30%] to 3.82% [0.99%] (p  0.001),
whereas the change in the placebo group, from 0.17% [1.04%] to 1.15% [1.14%], was not
significant. Analysis of covariation showed that the effect of metyrapone was significant (p 
0.034).
CONCLUSIONS Inhibition of cortisol production by metyrapone ameliorates the endothelial dysfunction seen
in depression, suggesting that the mechanism of the endothelial dysfunction may involve
cortisol. (J Am Coll Cardiol 2006;48:170–5) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.078Cardiology Foundation
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epidemiologic evidence has shown depression to be an
ndependent risk factor for the subsequent development of
oronary heart disease (CHD), even after controlling for
ther risk factors such as smoking, although the biological
echanisms underlying this apparently causal association
re not yet known (1,2). It has recently been reported that
atients with newly diagnosed, untreated depression have
ndothelial dysfunction (3), and we showed similar dysfunc-
ion in young patients with treated depression whose mood
as normal at the time of the study and who had no other
onventional cardiovascular risk factors (4).
Endothelial dysfunction is a key factor in the atheroscle-
otic process, and is seen in association with all of the
raditional risk factors for atherosclerotic vascular disease,
ncluding smoking (5), diabetes (6), hypercholesterolemia
7), and hypertension (8), well before the development of
From the *Department of Cardiovascular Medicine, University of Birmingham,
irmingham, England; †Department of Psychological Medicine, St. Bartholomew’s
nd Royal London Hospital School of Medicine, London, England; ‡Department of
sychological Medicine, University of Wales College of Medicine, Cardiff, Wales;
nd the §Department of Cardiology, Great Ormond Street Hospital for Children,
ondon, England. This work was supported by the British Heart Foundation. The
rst two authors contributed equally to this work.e
Manuscript received August 18, 2004; revised manuscript received November 11,
005, accepted December 14, 2005.linically apparent disease. It therefore seems likely that
ndothelial dysfunction may play a role in the increased
HD risk associated with depression.
The pathophysiological basis for endothelial dysfunction
n depression is not yet known but may be related to
bnormal function of the hypothalamic-pituitary-adrenal
HPA) axis, which is a characteristic feature of depression.
uch abnormalities include cortisol hypersecretion (9), fail-
re of normal suppression of cortisol production after oral
examethasone (10), and loss of the normal circadian
hythm of cortisol secretion (11). The overall picture is of
mpaired feedback and consequent HPA axis hyperactivity.
owever, the extent of these abnormalities is variable
ithin a population with depression, and HPA axis function
ay perhaps best be described as dysregulated (12). As a
onsequence of this abnormal HPA axis function, it seems
robable that patients with depression are exposed to
enerally increased levels of cortisol, without necessarily
xhibiting frank hypercortisolemia, and in particular do not
njoy a normal circadian nocturnal nadir. Short-term oral
ortisol produces endothelial dysfunction in healthy subjects
13), and chronic elevation of cortisol is associated with
arly atherosclerosis (14). We therefore hypothesized that
ndothelial dysfunction in depression may be mediated, at
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July 4, 2006:170–5 Metyrapone and Endothelial Dysfunctioneast in part, by cortisol. To test this hypothesis we exam-
ned the acute effect of oral metyrapone, an inhibitor of
drenal 11-hydroxylase and therefore also of cortisol syn-
hesis, on endothelial dysfunction in treated patients with a
igorously defined diagnosis of recurrent major depression.
ETHODS
ubjects. We conducted a randomized, double-blind,
lacebo-controlled trial. Ethical permission was obtained
rom our local research ethics committee. We recruited
atients with a history of recurrent major depression com-
rising two or more episodes of unipolar depression of at
east moderate severity, separated by at least two months of
emission, as defined by the Diagnostic and Statistical
anual of Mental Disorders (DSM)-IV and the Interna-
ional Classification of Diseases and Related Health Prob-
ems (ICD)-10 (15,16). Exclusion criteria included a history
f psychotic symptoms that were mood incongruent or
resent when there was no evidence of a mood disturbance,
ntravenous drug use with a previous diagnosis of depen-
ency, depression occurring solely in relation to alcohol or
ubstance abuse, or depression occurring secondary to med-
cal illness or medication. All patients were treated and in
emission at the time of the study.
Patients were interviewed using the Schedule for Clinical
ssessments in Neuropsychiatry (SCAN), a set of instru-
ents validated in assessing, measuring, and classifying the
sychopathology and behavior associated with the major
dult psychiatric disorders. The ratings from the SCAN
nterview were entered into CATEG5 (World Health
rganization, Division of Mental Health, Geneva, Swit-
erland), a computerized scoring program that provides
iagnoses according to DSM-IV and ICD-10 operational
efinitions. We also recruited healthy control subjects to
rovide an age- and gender-matched reference range for
rachial artery flow-mediated dilation (FMD). Exclusion
riteria for both groups included a history of heart disease or
ny acquired risk factors for CHD (smoking within the last
0 years, hypertension, diabetes mellitus, plasma cholesterol
6.3 mmol/l), age18 years or55 years, body mass index
30 kg/m2, current pregnancy or menopause or any other
ondition, drug treatment, or dietary supplements known or
ikely to affect the measured variables.
Subjects were initially studied in the morning beginning
Abbreviations and Acronyms
ANCOVA  analysis of covariance
CHD  coronary heart disease
ECG  electrocardiogram
FMD  flow-mediated dilation
GTN  glyceryl trinitrate
GTNMD  glyceryl trinitrate-mediated dilation
HPA  hypothalamic-pituitary-adrenal
NO  nitric oxidet 8:30 AM, having fasted and avoided alcohol for at least e4 h and caffeine for at least 12 h. On arrival their height
nd weight were measured, their cardiovascular system was
xamined, and a 12-lead electrocardiogram (ECG) was
erformed. After attachment to an ECG monitor and
tting of a Portapres noninvasive continuous blood pressure
onitor (TNO Biomedical Instrumentation, Affligem, Bel-
ium), subjects rested supine in a quiet, temperature-
ontrolled environment for 20 min.
ssessment of endothelial function. Brachial artery FMD
as then measured using a previously validated technique
17). Briefly, high-resolution ultrasound (7.5 MHz) was
sed to visualize the brachial artery above its bifurcation at
he elbow. An M-mode ultrasound image was fed to a wall
racking system (Vadirec 101, Medical Systems Arnhem,
osterbrek, the Netherlands), which was able to determine
he diastolic diameter of the artery with a resolution of 10
m. All measurements were performed by a single observer.
or measurement of brachial artery diameter at baseline,
ntraobserver variability was 0.73% for subjects with depres-
ion and 0.53% for control subjects. A wrist cuff was inflated
o and maintained at between 250 and 300 mm Hg for five
in and then released, causing reactive hyperemia in the
and, which in turn led to increased flow through the
bserved segment of brachial artery. Increased flow through
n artery increases the shear stress at the blood-endothelium
nterface and stimulates healthy endothelial cells to produce
he vasodilator nitric oxide (NO). Some of the NO pro-
uced diffuses into the vascular smooth muscle layer adja-
ent to the endothelium, inducing relaxation and vessel
ilation. The dilation of the brachial artery in response to
ncreased flow—the FMD—was measured at one-min in-
ervals for the next eight min. The greatest change from
aseline within the first three min was taken to be FMD,
nd was expressed as a percent of baseline diameter. Once
he artery had returned to baseline diameter, 1 ml of glyceryl
rinitrate (GTN) solution containing 50 g of GTN was
dministered sublingually and brachial artery dilation was
easured 3 min later, as a measure of glyceryl trinitrate-
ediated endothelium-independent dilation (GTNMD).
lood sampling. With the subjects still supine, blood was
aken for measurement of plasma urea and electrolytes,
lucose, triglyceride, cholesterol (total, high-density, and
ow-density), cortisol, and full blood count, all of which
ere analyzed in our hospital’s main laboratory. After
enesection the subjects were allowed to sit up and were
iven a standard low-fat snack and a drink. The purpose of
he control group was to provide normal baseline FMD
easurements for comparison with the depression group,
nd they were not studied further after the morning visit.
etyrapone/placebo. Subjects with depression were ran-
omized in a double-blind fashion to one of two groups: the
ntervention group was given metyrapone 750 mg with their
nack, and a further 750-mg dose to be taken with their
idday meal 3.5 h later. The placebo group was given
atching placebos. We chose this dosing schedule becausearlier work has shown that this regimen produces a
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Metyrapone and Endothelial Dysfunction July 4, 2006:170–5ignificant reduction in plasma cortisol at 6 h and is well
olerated (18). Subjects then left the laboratory, and were
sked to return 5 h later. They were asked to avoid heavy
hysical work or exercise in the interval between their visits.
hey were also asked to continue abstaining from alcohol
nd caffeinated drinks and to avoid fatty foods. In the
nterval between tests, they completed the Beck Depression
nventory as a measure of their current symptoms.
eturn visit. On their return, subjects were placed in a
upine position and were connected to the ECG and
ortapres as before. The FMD was measured, and a blood
ample was obtained for measurement of plasma cortisol.
he FMD was thus measured approximately 6 h after the
rst dose of metyrapone/placebo. Finally, subjects under-
ent a brief structured interview so that they might be
cored on the Brief Anxiety Scale questionnaire.
able 1. Baseline Characteristics of Depression and Control
roups
Characteristic Depression Control p
nthropomorphic
Age (yrs) 40.1 [1.88] 39.5 [1.7] NS
Male (n) 8/30 (27%) 17/36 (47%) NS
Body mass index 24.4 [0.58] 24.5 [0.53] NS
Brachial artery diameter (mm) 2.90 [0.13] 2.99 [0.09] NS
ematologic
Total cholesterol (mmol/l) 4.60 [0.16] 4.52 [0.16] NS
HDL cholesterol (mmol/l) 1.56 [0.09] 1.46 [0.06] NS
LDL cholesterol (mmol/l) 2.58 [0.15] 2.59 [0.15] NS
Triglycerides (mmol/l) 1.01 [0.13] 0.99 [0.10] NS
Fasting glucose (mmol/l) 4.78 [0.09] 4.86 [0.09] NS
emodynamic
Systolic BP (mm Hg) 114.6 [2.7] 112.7 [2.3] NS
Diastolic BP (mm Hg) 74.2 [1.8] 70.0 [1.4] 0.066
Flow-mediated dilation (%) 1.27 [0.91] 4.37 [0.59] 0.001
GTN mediated dilation (%) 13.5 [1.12] 11.9 [1.23] NS
S  p  0.25. Values in brackets are SEM.
BP  blood pressure; GTN  glyceryl trinitrate; HDL  high-density lipopro-
ein; LDL  low-density lipoprotein.Figure 1. Brachial artery diameter change over time profiles: patietatistical analysis. Group results are expressed as mean
standard error of mean]. Comparison of means was per-
ormed within groups using the Student paired t test and
etween groups using Student unpaired t test. The effect of
lacebo/metyrapone on change in cortisol level and on
hange in FMD was assessed by analysis of covariance
ANCOVA). A p value of 0.05 was considered
ignificant.
ESULTS
aseline. Thirty-two patients with depression were en-
olled and randomized, but two were subsequently excluded
ecause of technically inadequate initial FMD studies.
hirty completed the study (metyrapone  15). We also
easured brachial artery FMD in 36 healthy control sub-
ects at baseline.
Depression and control groups were well matched for
nthropomorphic and hematological characteristics. There
as no difference in systolic blood pressure between groups,
ut diastolic blood pressure tended to be higher in the
epression group (Table 1). The FMD was significantly
mpaired in the depression group, of whom 14 showed a
aradoxical vasoconstriction in response to hyperemia, giv-
ng a negative overall value for FMD (1.27% [0.91%] vs.
.37% [0.59%], p  0.001). Paradoxical vasoconstriction is
n indicator of endothelial dysfunction and has previously
een reported in disease-related and experimentally induced
ndothelial dysfunction in epicardial coronary arteries
19,20) and in brachial arteries (21–25) using the wrist cuff
echnique (17). The profile of brachial artery diameter
hange over time for the depression and control groups is
hown in Figure 1. Within the depression group, the
lacebo and metyrapone groups were well matched for all
haracteristics (Table 2). They were taking a variety ofnts and control subjects (morning flow-mediated dilation).
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July 4, 2006:170–5 Metyrapone and Endothelial Dysfunctionrescribed antidepressants (Table 3). The number taking
ach type of agent was broadly similar between groups.
There was no significant difference at baseline between
he placebo and metyrapone groups for FMD (0.17%
1.04%] vs. 2.72% [1.30%], p  0.11) or GTNMD
13.7% [1.73%] vs. 13.2% [1.67%], p  0.84). Paradoxical
asoconstriction occurred in six subjects in the placebo
roup and eight in the metyrapone group. Cortisol did not
iffer significantly at baseline between placebo and metyrap-
ne groups (359.4 nmol/l [26.0 nmol/l] vs. 342.3 nmol/l
29.6 nmol/l]; p  0.67).
eturn visit. On the return visit, FMD was lower in the
lacebo than in the metyrapone group (1.15% [1.14%] vs.
.82% [0.99%]) and was not significantly different from
aseline. Paradoxical vasoconstriction occurred in five of the
lacebo group patients and two of the metyrapone group
atients. In the metyrapone group, there was a significant
ncrease in FMD (from 2.72% [1.30%] to 3.82% [0.99%],
 0.001). The ANCOVA including baseline FMD as a
ovariate showed that the effect of metyrapone on FMD was
ignificant (p  0.034) (Fig. 2). The GTNMD did not
hange significantly in either group between visits. On the
eturn visit, it was 13.8% [1.8%] and 15.2% [1.4%] in the
lacebo and metyrapone groups, respectively.
As expected on the basis of its diurnal pattern, which is not
ompletely lost in depression, and habituation to the laboratory
nvironment, plasma cortisol decreased in the placebo group
rom 359.4 nmol/l [26.0 nmol/l] in the morning to 278.3
mol/l [34.8 nmol/l] in the afternoon (p  0.039). However,
n the metyrapone group, the decrease was much more marked,
rom 342.3 nmol/l [29.6 nmol/l] to 83.7 nmol/l [6.0 nmol/l]
p  0.001), as anticipated. By ANCOVA, using baseline
alues as covariate, the effect of metyrapone on cortisol was
able 2. Baseline Characteristics of Placebo and Metyrapone
roups
Characteristic Placebo Metyrapone p
nthropomorphic
Age (yrs) 39.4 [2.93] 40.7 [2.42] NS
Male (n) 4/15 (27%) 4/15 (27%) NS
Body mass index 25.3 [0.76] 23.5 [0.82] NS
Brachial artery diameter (mm) 2.90 [0.17] 2.91 [0.20] NS
ematologic
Total cholesterol (mmol/l) 4.65 [0.23] 4.54 [0.24] NS
HDL cholesterol (mmol/l) 1.54 [0.14] 1.58 [0.11] NS
LDL cholesterol (mmol/l) 2.63 [0.22] 2.52 [0.21] NS
Triglycerides (mmol/l) 1.05 [0.13] 0.96 [0.13] NS
Glucose (mmol/l) 4.91 [0.12] 4.64 [0.13] NS
Cortisol (nmol/l) 359.4 [25.9] 342.4 [29.6] NS
emodynamic
Systolic BP (mm Hg) 116.7 [3.0] 112.5 [4.4] NS
Diastolic BP (mm Hg) 75.5 [2.4] 72.9 [2.7] NS
uestionnaire scores
Beck Depression Inventory 16.0 [2.6] 18.2 [2.4] NS
Basic Anxiety Scale 14.0 [1.8] 13.5 [1.9] NS
S  p  0.25. Values in brackets are SEM.
Abbreviations as in Table 1.ignificant (p  0.001).
i
sThere was no significant correlation between cortisol
evels and FMD at baseline or after metyrapone. There was
o significant correlation between Beck Depression Inven-
ory or Brief Anxiety Scale scores and FMD.
ISCUSSION
n this study, we confirm our report of severe endothelial
ysfunction in patients with prior depression but no other
stablished cardiovascular risk factors. We also show that
etyrapone, an inhibitor of cortisol biosynthesis, markedly
ugments brachial artery FMD in these patients.
The degree of impairment of brachial artery FMD in
hese patients was marked; indeed, many of the patients had
mild transient reduction of brachial artery diameter after
elease of the wrist cuff. The magnitude of FMD varies
ubstantially with the technique used. The widely used
pper arm occlusion technique results in substantially higher
MD than the forearm or wrist cuff techniques (17,26).
ild constrictor responses are observed in many patients
ith severe endothelial dysfunction (by ourselves and by
thers) using the wrist cuff technique (4,17) but are not
eported with the upper arm cuff technique. Indeed, the
MD observed in the present cohort of patients with
reated depression is very similar to what we previously
eported in a separate cohort of such patients (4,17).
hereas the inhibitor of NO synthesis NG-monomethyl
-arginine blocked 40% of brachial artery FMD after
elease of the upper arm cuff, it completely blocked FMD
fter release of the wrist cuff; indeed, as in our study, there
as a small brachial artery constrictor response (of approx-
mately 2.5%) (17). Our observations (which were obtained
sing the wrist cuff technique) therefore imply a marked
mpairment of NO-mediated endothelium-dependent vaso-
ilation of the brachial artery in patients with a prior history
f depression. Brachial artery dilation in response to the NO
onor GTN was normal. This may provide at least part of
he explanation for the increased risk of cardiovascular
vents associated with depressive illness (1,2). Endothelial
ysfunction manifested as impaired brachial artery FMD is
ssociated with all of the known cardiovascular risk factors
nd is present before clinical manifestations of atheroscle-
able 3. Antidepressant Therapy
Antidepressants Placebo* Metyrapone†
ricyclic or tricyclic-like 2 4
SRI 5 3
ARI 2 0
AOI 0 1
NRI 4 2
ithium 1 1
one or noncompliant 3 6
otal 17 17
One patient was taking an NARI and TCA-like drug, and one was taking an SNRI
nd lithium. †One patient was taking an SNRI and TCA-like drug, and one was
aking an SNRI and lithium.
NARI  norepinephrine reuptake inhibitor; MAOI  monoamine oxidase
nhibitor; SNRI serotonin and norepinephrine reuptake inhibitor; SSRI selective
erotonin reuptake inhibitor.
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Metyrapone and Endothelial Dysfunction July 4, 2006:170–5osis (5–8), and has been shown to predict the presence of
reclinical coronary artery disease (27).
Our observation that metyrapone substantially aug-
ented brachial artery FMD in patients with a prior history
f depression suggests that cortisol may play an important
ole in mediating endothelial dysfunction in these patients.
etyrapone reduces adrenal cortisol synthesis by inhibiting
he adrenal enzyme 11 hydroxylase. Consistent with this,
etyrapone therapy reduced plasma cortisol levels. We
ecently showed that metyrapone also prevented the impair-
ent of brachial artery FMD provoked by acute mental
tress in healthy young subjects (28), suggesting that this
ay also be mediated by cortisol. In that study we also
howed that metyrapone had no direct effect on NO release
rom human umbilical vein endothelial cells, therefore a
irect effect of metyrapone on endothelial function, inde-
endent of its effect on cortisol, is very unlikely. A previous
tudy has reported that five days of treatment with oral
ortisol impaired the forearm vasodilator response to the
ndothelium-dependent agonist acetylcholine (29). The
lasma cortisol levels achieved in these patients were,
owever, substantially higher than the modest elevation
een typically in acute episodes of depression (30). In treated
atients who are in remission, morning plasma cortisol
evels are typically within the normal range (as in this study).
evertheless, there is often evidence of HPA axis dysregu-
ation, with loss of normal circulation variation of cortisol
ecretions (31). This may explain in part the lack of a
orrelation between morning plasma cortisol levels and
mpairment of brachial artery FMD in this study. Further-
ore, local vascular concentrations of cortisol are likely to
e much more important than plasma concentrations. Local
issue levels of cortisol are influenced by activity of the two
soenzymes of II-beta hydroxysteroid dehydrogenase
Figure 2. Change in flow-mediated dHSD). The type I enzyme catalyses the conversion of 2nactive cortisone to active cortisol, and the type II enzyme
atalyses the opposite reaction (31). Expression of these
nzymes has been reported in the human vessels (32).
nterestingly, in addition to inhibiting adrenal cortisol
iosynthesis, metyrapone inhibits type I beta-HSD and may
herefore have greater effects on tissue cortisol concentra-
ions than on plasma concentrations (33).
Several possible mechanisms may mediate the adverse
ffect of cortisol on endothelial function. Glucocorticoids
eem to inhibit NO synthesis by both endothelial nitric
xide synthase and inducible nitric oxide synthase in cell and
issue models via both a direct mechanism (34) and reduced
roduction of the essential cofactor tetrahydrobiopterin
35). Glucocorticoids also have recently been shown to
nhance vascular superoxide production (36).
tudy limitations. For technical reasons, we were unable to
uantify reactive hyperemia after cuff deflation. We cannot
herefore exclude the theoretical possibility that metyrapone
roduced a significant increase in the reactive hyperemic
esponse via an unknown mechanism, and that a greater flow
timulus rather than improved endothelial function was re-
ponsible for the enhanced FMD observed. This is unlikely.
ignificance of the findings. Our findings strongly support
role for cortisol in mediating endothelial dysfunction in
epression. Cortisol is also thought to play a role in the
athophysiology of the depression (37). Although metyrapone
s not itself suitable as a therapeutic agent (although it has been
ried in the past), our findings indicate a possible future
irection in pharmacotherapy aimed at reducing CHD risk.
eprint requests and correspondence: Dr. Michael P. Fren-
eaux, Department of Cardiovascular Medicine, The Medical
chool, University of Birmingham, Edgbaston, Birmingham, B15
n (FMD) after placebo/metyrapone.TT, United Kingdom. E-mail: m.p.frenneaux@bham.ac.uk.
R1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
175JACC Vol. 48, No. 1, 2006 Broadley et al.
July 4, 2006:170–5 Metyrapone and Endothelial DysfunctionEFERENCES
1. Hemingway H, Marmot M. Evidence based cardiology: psychosocial
factors in the aetiology and prognosis of coronary heart disease.
Systematic review of prospective cohort studies. BMJ 1999;318:
1460–7.
2. Rugulies R. Depression as a predictor for coronary heart disease. A
review and meta-analysis. Am J Prev Med 2002;23:51–61.
3. Rajagopalan S, Brook R, Rubenfire M, et al. Abnormal brachial artery
flow-mediated vasodilation in young adults with major depression.
Am J Cardiol 2001;88:196–8.
4. Broadley AJ, Korszun A, Jones CJ, et al. Arterial endothelial function
is impaired in treated depression. Heart 2002;88:521–3.
5. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette
smoking is associated with dose-related and potentially reversible
impairment of endothelium-dependent dilation in healthy young
adults. Circulation 1993;88:2149–55.
6. Goodfellow J, Ramsey MW, Luddington LA, et al. Endothelium and
inelastic arteries: an early marker of vascular dysfunction in non-insulin
dependent diabetes. BMJ 1996;312:744–5.
7. Chowienczyk PJ, Watts GF, Cockcroft JR, et al. Impaired
endothelium-dependent vasodilation of forearm resistance vessels in
hypercholesterolaemia. Lancet 1992;340:1430–2.
8. Panza JA, Quyyumi AA, Brush JE Jr., et al. Abnormal endothelium-
dependent vascular relaxation in patients with essential hypertension.
N Engl J Med 1990;323:22–7.
9. Charlton BG, Leake A, Wright C, et al. A combined study of cortisol,
ACTH and dexamethasone concentrations in major depression. Mul-
tiple time-point sampling. Br J Psychiatry 1987;150:791–6.
0. Ribeiro SC, Tandon R, Grunhaus L, et al. The DST as a predictor of
outcome in depression: a meta-analysis. Am J Psychiatry 1993;150:
1618–29.
1. Trimble MR. Anticonvulsant-induced psychiatric disorders. The role
of forced normalisation. Drug Saf 1996;15:159–66.
2. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor
for coronary artery disease: evidence, mechanisms, and treatment.
Psychosom Med 2004;66:305–15.
3. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardio-
vascular disease. Hypertension 2000;36:912–6.
4. Troxler RG, Sprague EA, Albanese RA, et al. The association of
elevated plasma cortisol and early atherosclerosis as demonstrated by
coronary angiography. Atherosclerosis 1977;26:151–62.
5. American Psychiatric Association. Diagnostic and Statistical Manual
of Mental Disorders. 4th edition. Washington, DC: American Psy-
chiatric Association, 1994.
6. World Health Organization. International Statistical Classification of
Diseases and Related Health Problems. 10th edition. Geneva, Swit-
zerland: World Health Organization, 1992.
7. Doshi SN, Naka KK, Payne N, et al. Flow-mediated dilation follow-
ing wrist and upper arm occlusion in humans: the contribution of nitric
oxide. Clin Sci (Lond) 2001;101:629–35.
8. Young EA, Lopez JF, Murphy-Weinberg V, et al. Normal pituitary
response to metyrapone in the morning in depressed patients: impli-
cations for circadian regulation of corticotropin-releasing hormone
secretion. Biol Psychiatry 1997;41:1149–55.
9. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are
responsive to changing blood flow: an endothelium-dependent mech-
anism that fails in patients with atherosclerosis. J Am Coll Cardiol
1990;16:349–56.0. Werns SW, Walton JA, Hsia HH, et al. Evidence of endothelial
dysfunction in angiographically normal coronary arteries of patients
with coronary artery disease. Circulation 1989;79:287–91.
1. Bellamy MF, McDowell IF, Ramsey MW, et al. Hyperhomocysteine-
mia after an oral methionine load acutely impairs endothelial function
in healthy adults. Circulation 1998;98:1848–52.
2. Bode-Boger SM, Muke J, Surdacki A, et al. Oral L-arginine improves
endothelial function in healthy individuals older than 70 years. Vasc
Med 2003;8:77–81.
3. Davis SR, Goldstat R, Newman A, et al. Differing effects of low-dose
estrogen-progestin therapy and pravastatin in postmenopausal hyper-
cholesterolemic women. Climacteric 2002;5:341–50.
4. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. Oral L-arginine
improves endothelial dysfunction in patients with essential hyperten-
sion. Int J Cardiol 2002;86:317–23.
5. Nawawi H, Osman NS, Annuar R, et al. Soluble intercellular adhesion
molecule-1 and interleukin-6 levels reflect endothelial dysfunction in
patients with primary hypercholesterolaemia treated with atorvastatin.
Atherosclerosis 2003;169:283–91.
6. Betik AC, Luckham VB, Hughson RL. Flow-mediated dilation in
human brachial artery after different circulatory occlusion conditions.
Am J Physiol Heart Circ Physiol 2004;286:H442–8.
7. Kuvin JT, Patel AR, Sliney KA, et al. Peripheral vascular endothelial
function testing as a noninvasive indicator of coronary artery disease.
J Am Coll Cardiol 2001;38:1843–9.
8. Broadley AJ, Korszun A, Abdelaal E, et al. Inhibition of cortisol
production with metyrapone prevents mental stress-induced endothe-
lial dysfunction and baroreflex impairment. J Am Coll Cardiol 2005;
46:344–50.
9. Mangos GJ, Walker BR, Kelly JJ, et al. Cortisol inhibits cholinergic
vasodilation in the human forearm. Am J Hypertens 2000;13:1155–60.
0. Steiger A, von Bardeleben U, Herth T, et al. Sleep EEG and nocturnal
secretion of cortisol and growth hormone in male patients with
endogenous depression before treatment and after recovery. J Affect
Disord 1989;16:189–95.
1. Steiger A, Holsboer F. Nocturnal secretion of prolactin and cortisol
and the sleep EEG in patients with major endogenous depression
during an acute episode and after full remission. Psychiatry Res
1997;72:81–8.
2. Hatakeyama H, Inaba S, Miyamori I. 11-hydroxysteroid dehydro-
genase in cultured human vascular cells. Possible role in the develop-
ment of hypertension. Hypertension 1999;33:1179–84.
3. Raven PW, Checkley SA, Taylor NF. Extra-adrenal effects of me-
tyrapone include inhibition of the 11-oxoreductase activity of 11
-hydroxysteroid dehydrogenase: a model for 11-HSD I deficiency.
Clin Endocrinol (Oxf) 1995;43:637–44.
4. Rogers KM, Bonar CA, Estrella JL, et al. Inhibitory effect of
glucocorticoid on coronary artery endothelial function. Am J Physiol
Heart Circ Physiol 2002;283:H1922–8.
5. Simmons WW, Ungureanu-Longrois D, Smith GK, et al. Glucocor-
ticoids regulate inducible nitric oxide synthase by inhibiting tetrahy-
drobiopterin synthesis and L-arginine transport. J Biol Chem 1996;
271:23928–37.
6. Iuchi T, Akaike M, Mitsui T, et al. Glucocorticoid excess induces
superoxide production in vascular endothelial cells and elicits vascular
endothelial dysfunction. Circ Res 2003;92:81–7.
7. Lee AL, Ogle WO, Sapolsky RM. Stress and depression: possible
links to neuron death in the hippocampus. Bipolar Disord 2002;4:
117–28.
